Teva Pharmaceutical Industries Overview
- Year Founded
-
1901
- Status
-
Public
- Employees
-
35,686
- Stock Symbol
-
TEVA
- Investments
-
94
- Share Price
-
$14.29
- (As of Thursday Closing)
Teva Pharmaceutical Industries General Information
Description
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Contact Information
Website
www.tevapharm.comCorporate Office
- Dvorah Haneviah 124
- Tel Aviv 6944020
- Israel
Corporate Office
- Dvorah Haneviah 124
- Tel Aviv 6944020
- Israel
Teva Pharmaceutical Industries Timeline
Teva Pharmaceutical Industries Stock Performance
As of 24-Apr-2025, Teva Pharmaceutical Industries’s stock price is $14.29. Its current market cap is $16.4B with 1.15B shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $14.29 | $14.32 | $12.87 - $22.50 | $16.4B | 1.15B | 1.48M | -$1.45 |
Teva Pharmaceutical Industries Financials Summary
As of 31-Dec-2024, Teva Pharmaceutical Industries has a trailing 12-month revenue of $16.5B.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 41,403,023 | 41,403,023 | 30,512,939 | 30,493,700 |
| Revenue | 16,544,000 | 16,544,000 | 15,845,000 | 14,925,000 |
| EBITDA | 777,000 | 777,000 | 1,558,000 | (925,000) |
| Net Income | (1,639,000) | (1,639,000) | (559,000) | (2,446,000) |
| Total Assets | 39,326,000 | 39,326,000 | 43,479,000 | 44,011,000 |
| Total Debt | 18,079,000 | 18,079,000 | 20,153,000 | 21,561,000 |
Teva Pharmaceutical Industries Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Teva Pharmaceutical Industries Comparisons
Industry
Financing
Details
Teva Pharmaceutical Industries Competitors (27)
One of Teva Pharmaceutical Industries’s 27 competitors is AbbVie, a Corporation company based in North Chicago, IL.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| AbbVie | Corporation | North Chicago, IL | ||||
| Pfizer (Pharmaceuticals) | Corporation | New York, NY | ||||
| Dr. Reddy's Laboratories | Corporation | Hyderabad, India | ||||
| Roche | Corporation | Basel, Switzerland | ||||
| SynCore Biotechnology Company | Corporation | Yilan City, Taiwan |
Teva Pharmaceutical Industries Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Teva Pharmaceutical Industries Patents
Teva Pharmaceutical Industries Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240238308-A1 | Olanzapine compositions and methods of use | Pending | 10-Jan-2023 | ||
| US-20240325408-A1 | Olanzapine compositions and methods of use | Active | 10-Jan-2023 | ||
| US-12220418-B2 | Olanzapine compositions and methods of use | Active | 10-Jan-2023 | ||
| JP-2025506783-A | Solid forms of gusacitinib | Pending | 23-Feb-2022 | ||
| US-20250066327-A1 | Solid state forms of danicopan and process thereof | Pending | 21-Feb-2022 | C07D401/14 |
Teva Pharmaceutical Industries Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Teva Pharmaceutical Industries Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Teva Pharmaceutical Industries Investments & Acquisitions (94)
Teva Pharmaceutical Industries’s most recent deal was a Seed Round with CombinAble.AI for . The deal was made on 15-Mar-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| CombinAble.AI | 15-Mar-2024 | Seed Round | Other Healthcare Technology Systems | ||
| DenovAI | 28-Feb-2023 | Seed Round | Biotechnology | ||
| Bayer Classics | 01-Jul-2022 | Merger/Acquisition | Pharmaceuticals | ||
| MetaSight | 01-Apr-2022 | Early Stage VC | Biotechnology | ||
| Remedix Care | 01-Sep-2019 | Joint Venture | Pharmaceuticals |
Teva Pharmaceutical Industries ESG
Risk Overview
Risk Rating
Updated March, 21, 2025
20.58 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,109
Rank
Percentile
Pharmaceuticals
Industry
of 861
Rank
Percentile
Pharmaceuticals
Subindustry
of 430
Rank
Percentile
Teva Pharmaceutical Industries Exits (42)
Teva Pharmaceutical Industries’s most recent exit was on 15-Aug-2019 from Veoli. The exit was categorized as with 4 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Veoli | 15-Aug-2019 | Completed |
|
||
| Heptares | 18-May-2017 | Completed |
|
||
| WaVe Life Sciences | 14-Dec-2015 | Completed |
|
||
| Microchips Biotech | 18-Jun-2015 | Completed |
|
||
| Amwell | 02-Jun-2015 | Later Stage VC | Completed |
Teva Pharmaceutical Industries Affiliates
Subsidiaries (13)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Gecko Health Innovations | Cambridge, MA | 2012 | |
| Immuneering | Cambridge, MA | 2008 | |
| Lotus Labs (Laboratory) | Bangalore, India | 2001 | |
| Theramex Italy | Milan, Italy | 1999 | |
| MicroDose Therapeutx | South Brunswick Township, NJ | 1998 |
Teva Pharmaceutical Industries FAQs
-
When was Teva Pharmaceutical Industries founded?
Teva Pharmaceutical Industries was founded in 1901.
-
Where is Teva Pharmaceutical Industries headquartered?
Teva Pharmaceutical Industries is headquartered in Tel Aviv, Israel.
-
What is the size of Teva Pharmaceutical Industries?
Teva Pharmaceutical Industries has 35,686 total employees.
-
What industry is Teva Pharmaceutical Industries in?
Teva Pharmaceutical Industries’s primary industry is Pharmaceuticals.
-
Is Teva Pharmaceutical Industries a private or public company?
Teva Pharmaceutical Industries is a Public company.
-
What is Teva Pharmaceutical Industries’s stock symbol?
The ticker symbol for Teva Pharmaceutical Industries is TEVA.
-
What is the current stock price of Teva Pharmaceutical Industries?
As of 24-Apr-2025 the stock price of Teva Pharmaceutical Industries is $14.29.
-
What is the current market cap of Teva Pharmaceutical Industries?
The current market capitalization of Teva Pharmaceutical Industries is $16.4B.
-
What is Teva Pharmaceutical Industries’s current revenue?
The trailing twelve month revenue for Teva Pharmaceutical Industries is $16.5B.
-
Who are Teva Pharmaceutical Industries’s competitors?
AbbVie, Pfizer (Pharmaceuticals), Dr. Reddy's Laboratories, Roche, and SynCore Biotechnology Company are some of the 27 competitors of Teva Pharmaceutical Industries.
-
What is Teva Pharmaceutical Industries’s annual earnings per share (EPS)?
Teva Pharmaceutical Industries’s EPS for 12 months was -$1.45.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
